Should I keep taking Deuterated Colexitinib Tablets?

Deuterated colexitinib tablets (trade names such as Sondido, etc.) are drugs used to treat adult patients with moderate to severe plaque psoriasis who are suitable for systemic therapy or phototherapy. It works by inhibiting specific inflammatory signaling pathways (such as the Janus kinase pathway), thereby effectively regulating immune responses and improving patients' skin symptoms.

The severity of a patient's condition is an important factor in determining whether long-term medication is needed. For patients with more severe disease, longer treatment may be required to maintain the stability of the disease. The patient's response to deuterated colexitinib tablets will also affect the duration of medication. If the patient shows significant efficacy in the early stages of treatment and the condition remains stable, the doctor may consider gradually reducing the dosage of medication or discontinuing the medication. On the other hand, if the effect is not good, the doctor may adjust the treatment plan.

The doctor will formulate a personalized treatment plan based on the patient's specific situation (such as illness, age, physical condition, etc.), including medication time, dosage, etc. Therefore, patients should follow their doctor's advice and not decide to stop or continue taking the medication on their own.

According to clinical trials and long-term follow-up data, deuterated colexitinib tablets have shown good safety during long-term use. The incidence of adverse events or serious adverse events did not increase significantly with the extension of medication time, and no new safety signals emerged.

Clinical trial results show that when patients with psoriasis are treated with deuterated colexitinib for a long period of time (such as 208 weeks), they can still maintain a high clinical response rate, and the efficacy will not attenuate as the treatment time is extended.